1. Impact of rosuvastatin on pulse-wave velocity in men with HIV at moderate cardiovascular risk.
- Author
-
Trevillyan JM, Dart A, Paul E, Dewar EM, Hall VG, and Hoy JF
- Subjects
- Humans, Male, Middle Aged, Double-Blind Method, Placebos administration & dosage, Adult, Sulfonamides therapeutic use, Sulfonamides pharmacology, Treatment Outcome, Pyrimidines, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Fluorobenzenes therapeutic use, Rosuvastatin Calcium therapeutic use, Rosuvastatin Calcium administration & dosage, HIV Infections drug therapy, HIV Infections complications, Pulse Wave Analysis, Cardiovascular Diseases
- Abstract
This single-centre substudy of a double-blind, randomized, placebo-controlled trial aimed to determine the effect of 96 weeks of rosuvastatin on pulse wave velocity (PWV) in men (n = 55, 54 years) with HIV at moderate cardiovascular risk (Framingham risk score 10-15%). PWV increased in both rosuvastatin [0.54 m/s standard error of difference (SED) 0.26] and placebo [0.50 m/s (SED 0.26), P = 0.896] arms, leading to no difference in PWV at week 96 [rosuvastatin 9.40 m/s (SE 0.31); placebo 9.21 m/s (SE0.31), P = 0.676]., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF